Importer of Record (IOR) for Multi‑Country MedTech Trials in Latin America: A Sponsor‑Ready Playbook

In Latin America, getting a first-in-human or early-stage MedTech study approved is only half the battle. The other half is operational: getting investigational devices, accessories, and consumables through customs reliably—on time, every time, across multiple countries.

That is why the Importer of Record (IOR) decision becomes a critical-path item for sponsors. An IOR strategy is not just “paperwork.” It is the control system that determines who is legally responsible for the import, who holds product registrations (when needed), how the shipment is classified, and who can react when a package is held.

This playbook explains what an IOR does in the context of MedTech clinical trials in Latin America, how to choose an IOR model for multi-country programs, and which checklists reduce the most common causes of delays.

What is an Importer of Record (IOR) in a clinical trial context?

An Importer of Record is the entity that assumes legal responsibility for bringing goods into a country. In MedTech clinical trials, the IOR is typically responsible for:

• Customs declaration and classification (HS codes, declared value, product description consistency)
• Regulatory alignment for investigational-use shipments (where applicable)
• Coordination with brokers and resolution of holds, inspections, and documentation requests
• Chain-of-custody documentation and receiving confirmation for sites
• Import compliance (licenses, tax IDs, authorizations, and record retention)

For a sponsor running a multi-country LATAM program, the IOR is a practical risk owner: when the shipment is delayed, the IOR is the party with standing to respond, correct documents, and release the goods.

Why the IOR decision becomes a critical path in Latin America

Multi-country execution introduces parallel risk. Even if each country has a clean regulatory path, supply chain variability can create staggered site activations and missed enrollment windows. Common delay drivers include:

• Inconsistent product descriptions between invoice, packing list, airway bill, and regulatory letters
• Misaligned declared value (e.g., “free of charge” shipments that trigger valuation questions)
• Unclear purpose-of-import (commercial vs investigational vs donation terminology)
• Missing or outdated IOR registrations (tax IDs, legal entity status, import licenses)
• Cold chain ambiguity (temperature ranges not specified, packaging validation gaps)

The impact is rarely isolated. A single held shipment can create a cascade: rescheduled site initiation visits, re-booked monitoring travel, delayed training, and protocol deviations when replacement components arrive late.

IOR models for multi-country LATAM MedTech trials (and how to choose)

There is no universal best model. The right answer depends on the investigational product profile, the number of countries, and how much operational control the sponsor needs.

Model A: Site or hospital as IOR

When it works: small studies, low-complexity devices, and highly experienced research institutions with established import processes.

Risks: sites often lack bandwidth for repeated customs interactions; import experience varies widely; accountability becomes fragmented across countries.

Model B: Local distributor as IOR

When it works: later-stage programs where a commercial partner already exists and can support consistent import flows.

Risks: distributor incentives may not match trial urgency; conflict may arise around product classification, pricing, or future commercial rights.

Model C: Sponsor-appointed specialized IOR/clinical logistics partner

When it works: multi-country studies, time-sensitive shipments, accessory-heavy devices, and programs requiring consistent compliance documentation.

Benefits: centralized process control, repeatable templates, proactive broker management, and stronger visibility across the supply chain.

Sponsor selection criteria should include: country coverage, medical product import track record, temperature-controlled capability (if relevant), speed of document turnaround, and documented escalation procedures.

The sponsor-ready IOR checklist (what to confirm before first shipment)

• Legal entity readiness: confirm the IOR’s legal registration, tax identifiers, and ability to act as importer for investigational medical products.
• Defined shipment purpose language: use consistent terms such as “investigational-use medical device for clinical study” and avoid mixed commercial language.
• Standard document pack: commercial invoice (even if no charge), packing list, airway bill, letter of authorization, and study documentation as required.
• HS code governance: lock a primary HS classification per SKU/component and document the rationale for re-use across shipments.
• Broker alignment: confirm who the broker is, how communications flow, and who can approve changes under time pressure.
• Receiving plan: define site receiving hours, quarantine process (if any), and confirmation steps to close the logistics loop.

In multi-country programs, treat this checklist as a controlled document. Once validated, it becomes the baseline for every country pack with only country-specific annexes.

How to reduce customs holds and avoid “silent delays”

Many delays occur because the sponsor does not hear about an issue until the shipment has already been held for days. Reduce that risk with:

• Pre-alerts: send document packs to the IOR/broker before shipment departure for pre-review.
• Single source of truth: maintain a shipment register shared with the IOR and the clinical team (SKU, lot/serial ranges, destination sites, temperature requirements).
• Escalation SLAs: require response times for holds (e.g., 2–4 hours during business days) and define who can approve revised declarations.
• Component rationalization: where possible, reduce “mixed shipments” with many line items that increase classification complexity.

Sponsors should also build a buffer into the activation plan. Even with a strong IOR, variability exists. The objective is not perfection; it is predictable, recoverable execution.

FAQ

Do we need one IOR per country for a multi-country LATAM trial?

Yes—imports occur at the country level, so each country requires an importer. The strategic decision is whether to use the same specialized partner (with local entities) across countries to standardize documentation and escalation.

Can we ship devices as “no commercial value” to simplify customs?

Not necessarily. “No commercial value” language can trigger valuation questions. A clearer approach is to declare an appropriate value and describe the purpose consistently as investigational-use for a clinical study.

What should sponsors measure to manage IOR performance?

Track time from shipment tender to customs release, number of holds per shipment, root causes of holds, and time-to-response during escalation. These metrics quickly reveal whether the IOR process is improving or drifting.

Bottom line: In Latin America, the IOR model is a study design decision as much as an operations decision. Define it early, standardize it across countries, and your activation timeline becomes far more reliable.